Treatment failure rates in both groups were lower than investigators expected.
Investigators of the SUMMIT study recently reported that patients who underwent open matrix-induced autologous chondrocyte treatment showed significant successful pain relief and functional improvement at 2 years. The prospective, randomized multicenter SUMMIT study was conducted to compare the matrix-induced autologous chondrocyte implant (MACI), which is placed via a mini-open procedure, to microfracture for symptomatic large femoral condyle or trochlear de- fects at 2-year follow-up.
“We had significantly better results with MACI vs. microfrac- ture,” based on the Knee Injury and Osteoarthritis Outcome Score (KOOS) for pain and function as the primary outcomes, Mats Brittberg, MD, PhD, told Orthopaedics Today Europe. “The most important part is to have the patients experience pain relief and long time durability. All other KOOS subscales were also statistically superior for the MACI implant.”
Read the full article in the September 2013 issue of the EFORT OTE newsletter
